GLP-1 Explained
62 articles

Conditions

GLP-1 beyond weight loss: the expanding indications.

GLP-1 Agonists & Addiction: Food Noise, Alcohol, Dopamine & Reward Circuitry Explained → GLP-1 Drugs and Addiction: The Surprising Evidence on Alcohol, Opioids, and Compulsive Eating → GLP-1 and Addiction: How Semaglutide Is Reducing Alcohol, Smoking, and Compulsive Behaviors Through the Brain's Reward System (2026) → GLP-1 and Addiction: Alcohol, Tobacco & Binge Eating Reward Circuitry → GLP-1 Agonists & Addiction: Dopamine, Alcohol, and the Reward System → GLP-1 Medications and Alcohol Cravings: The Dopamine Reward Pathway Explained → GLP-1 Agonists and Addiction: GLP-1 Receptors in the Nucleus Accumbens and VTA Suppress Dopamine Reward Signaling, Hendershot 2024 (Alcohol Clin Exp Res) Pilot RCT Shows −40% Alcohol Craving vs Placebo, Jerlhag Mesolimbic Pathway Research, Ozempic for Alcohol/Nicotine/Opioid Craving Reports, and What the "Food Noise" Suppression and Substance Craving Overlap Mean for Addiction Medicine (2026) → GLP-1 Agonists & Alzheimer's Disease: Liraglutide ELAD Trial, Semaglutide Norgaard 2024 JAMA, EVOKE Trial, Type 3 Diabetes, Neuroinflammation → GLP-1 & Alzheimer's Disease: Hölscher 2012 Neuroprotection, Semaglutide LIBRA Trial, GLP-1R in Hippocampus, BDNF Upregulation → GLP-1 and Alzheimer's: Why Neurologists Are Watching Semaglutide With Extraordinary Interest → GLP-1 Drugs and Fatty Liver (MASLD/NAFLD): What the Trial Data Shows (2026) → GLP-1 & Binge Eating Disorder: How Semaglutide Silences Food Noise → GLP-1 and Bone Density: GIP Receptor Biology, Bone Turnover Markers, Semaglutide Fracture Data, and Why Tirzepatide's Dual GIP/GLP-1 Action Matters for Skeletal Health → GLP-1 & Bone Health: Osteoporosis Risk, Fracture Studies & Protection Guide (2024) → GLP-1 and the Brain: Alzheimer's Risk Reduction, Parkinson's Neuroprotection, and SUSTAIN-6 Stroke Data (2026) → GLP-1 and the Brain: Nucleus Accumbens Reward Suppression, Food Noise Elimination, Semaglutide Alcohol Cravings (Klausen 2022 Rodent Data, SELECT Subgroup), Gambling/Shopping Reduction Reports, and the Emerging Addiction Medicine Hypothesis (2026) → GLP-1 Cardiovascular Benefits: LEADER Trial, Semaglutide Heart Disease, Atherosclerosis Mechanisms → GLP-1 and Heart Health: The SELECT Trial and Cardiovascular Benefits Explained (2026) → GLP-1 Cardiovascular Benefits: The SELECT Trial and Beyond (2026) → GLP-1 Agonists and Cardiovascular Outcomes: LEADER, SUSTAIN-6 & Heart Disease Guide → GLP-1 Cardiovascular Outcomes: SELECT Trial −20% MACE, LEADER, SUSTAIN-6, REWIND, STEP-HFpEF Heart Failure Data, and the Direct Cardiac Mechanisms Behind GLP-1 Cardioprotection → GLP-1 and Cardiovascular Protection: SELECT Trial (−20% MACE in Non-Diabetics), LEADER Trial, and How These Drugs Protect the Heart Beyond Weight Loss (2026) → GLP-1 & Cardiovascular Protection: SELECT Trial (N=17,604), LEADER Trial Liraglutide, Atherosclerosis Plaque Regression, −20% MACE → GLP-1 and Cardiovascular Disease: SELECT Trial → GLP-1 and Heart Disease: The SELECT Trial Explained (2026) → GLP-1 Drugs and Heart Health: Cardiovascular Benefits Beyond Weight Loss (2026) → GLP-1 Agonists for Fatty Liver Disease (MASH/NAFLD): What the Trials Show (2026) → GLP-1 for Fatty Liver (MASLD/NASH): Semaglutide and Tirzepatide Evidence (2026) → GLP-1 Drugs for PCOS: Weight Loss, Insulin Resistance, and Androgen Reduction (2026) → GLP-1 Agonists & the Immune System: Inflammation, Autoimmune Conditions & Cardiovascular Protection → GLP-1 and Kidney Disease: FLOW Trial (Perkovic 2024, NEJM, N=3,533, −24% Kidney+CV Events with Semaglutide), Renal Protection Mechanisms, GLP-1 vs SGLT2 Inhibitors for CKD, eGFR Trajectory, and First-Line Guidelines for T2DM with CKD (2026) → GLP-1 Agonists and Kidney Disease: FLOW Trial, CKD Protection & Dosing Guide → GLP-1 and Kidney Disease: FLOW Trial Semaglutide in CKD, eGFR Slope Improvement, Proteinuria Reduction, Cardiorenal Syndrome Mechanisms, and UACR as Renal Biomarker → GLP-1 Drugs and Kidney Health: FLOW Trial Results and Renal Protection (2026) → GLP-1 and Kidney Protection: CREDENCE and DAPA-CKD Trial Data, GLP-1 vs SGLT2 Inhibitor Renal Mechanisms, Intraglomerular Pressure, and Who Should Get Which Drug → GLP-1 Agonists and Kidney Protection: FLOW Trial, CKD & Diabetic Nephropathy Guide → GLP-1 Kidney Protection: FLOW Trial, Diabetic Nephropathy & Renal Mechanisms → GLP-1 Agonists, Male Fertility & Testosterone: The Obesity-Hypogonadism Connection → GLP-1 and Fatty Liver Disease (MASH/MASLD): ESSENCE Trial (Newsome 2024, NEJM, N=800 → GLP-1 Agonists for NAFLD & NASH: Semaglutide, Liver Fat Reduction & Fibrosis Guide → GLP-1 and NAFLD/NASH: SURMOUNT-NASH Tirzepatide 2024 Data, Hepatic Fat Reduction, Liver Fibrosis Improvement, and ALT Normalization → GLP-1 Agonists for PCOS: Insulin Resistance Mechanism, Liraglutide Ovulation Data, Androgen Excess Reduction, and the Emerging Fertility Evidence → GLP-1 for PCOS: Weight Loss, Insulin Resistance, and Fertility Outcomes (2026) → GLP-1 Drugs for PCOS: Semaglutide, Weight Loss, and Insulin Resistance (2026) → GLP-1 and PCOS: Insulin Resistance, Semaglutide Off-Label, and What the Evidence Shows (2026) → GLP-1 Agonists & PCOS: Insulin Resistance, Hormonal Effects & Metabolic Improvement → GLP-1 for PCOS: Why Endocrinologists Are Increasingly Prescribing Semaglutide Off-Label → GLP-1 Agonists for PCOS: Insulin Resistance, Weight Loss & Hormonal Benefits → GLP-1 Agonists for PCOS: Insulin Resistance, Hormonal Balance & Fertility → GLP-1 Agonists and PCOS: Insulin Resistance, Fertility & Semaglutide Evidence Guide → GLP-1 Agonists and Pregnancy: Fertility, Discontinuation Timing & Gestational Diabetes Guide → GLP-1 & Sleep Apnea: SURMOUNT-OSA Trial, Tirzepatide AHI Reduction 63%, Semaglutide OSA Data, vs. CPAP → GLP-1 and Sleep Apnea: SURMOUNT-OSA Tirzepatide 2024 Trial, −62.8% AHI Reduction, Pharyngeal Fat Mechanism, Hypoxic Burden Improvement, and Whether GLP-1 RAs Can Replace CPAP → GLP-1 and Sleep Apnea: SURMOUNT-OSA Trial, Tirzepatide AHI Reduction, Upper Airway Fat Mechanism, and Whether GLP-1s Can Replace CPAP → GLP-1 and Sleep Apnea: SURMOUNT-OSA Trial → GLP-1 Agonists and Sleep: Sleep Apnea, Circadian Rhythm & Melatonin Guide → GLP-1 and PCOS: Insulin Resistance as the Core Driver, Semaglutide Weight Loss Restoring Menstrual Cycles, Testosterone Reduction, Tirzepatide SURMOUNT-PCOS Data, Comparison With Metformin, and the Evidence-Based Protocol for GLP-1 in Polycystic Ovary Syndrome (2026) → Semaglutide and Bone Health: What the Research Actually Shows About Fracture Risk → The SELECT Trial: How Semaglutide Became the First Obesity Drug to Prove Cardiovascular Benefit → Semaglutide and Kidney Disease: The FLOW Trial Results Explained → Semaglutide and Male Fertility: What GLP-1 Drugs Do to Testosterone and Sperm → Semaglutide for Fatty Liver Disease: The MASH Trials That Are Reshaping Hepatology →
Losing weight? Don't lose muscle.
Up to 40% of GLP-1 weight loss can be muscle. The GLP-1 Protein Playbook shows you exactly how to protect it — with 25 high-protein meals that go down easy on a killed appetite.
Get the Playbook → $19